Login Register Cart 0
Review Article

计算机辅助药物设计工具概述及其在抗糖尿病药物设计中的最新应用

卷 22, 期 10, 2021

发表于: 19 November, 2020

页: [1158 - 1182] 页: 25

弟呕挨: 10.2174/1389450121666201119141525

价格: $65

conference banner
摘要

背景：在这个快速发展的时代，现在可以通过转换为存储信息的数据集来轻松访问高吞吐量数据。这些信息对于通过计算机辅助药物设计 (CADD) 优化假设和药物设计很有价值。如今，我们可以探索 CADD 在纳米技术、生物化学、医学科学、分子生物学等各个学科中的作用。 方法：我们使用相关数据库搜索有价值的文献，并使用给定的关键词，如计算机辅助药物设计、抗糖尿病、药物设计等。我们检索了所有近期的有价值文章，并讨论了计算在抗糖尿病药物设计中的作用。糖尿病药剂。 结果：为了促进药物发现过程，计算方法在药物发现的整个管道中设置了里程碑，从靶标识别和作用机制到先导物和候选药物的识别。与此同时，还致力于描述计算机模拟研究在预测吸收、分布、代谢、排泄和毒性特征方面的重要性。因此，在全球范围内，CADD 被用于研究 QSAR、虚拟筛选、蛋白质结构预测、量子化学、材料设计、物理和生物特性预测的各种工具所接受。 结论：计算机辅助工具被用作不同疾病领域的药物发现工具，在此我们回顾了信息技术和化学信息学工具在发现抗糖尿病药物方面的协作方面，同时考虑到治疗糖尿病药物日益增长的重要性。糖尿病。

关键词: 抗糖尿病药、计算机辅助药物设计、分子对接、QSAR、虚拟筛选、化学信息学工具。

« Previous Next »
图形摘要

[1]
Sharma SK, Sharma E, Sharma Y. A review: Recent computational approaches in medicinal chemistry: Computer aided drug designing and delivery. J Pharm Innov 2017; 6: 5-10.
[2]
Wikberg J, Spjuth O, Eklund M, Lapins M. Chemoinformatics Taking Biology into Account: Proteochemometrics.Guha R, Bender A, editors Comput Approaches Cheminformatics Bioinforma. 2011th In: ed Hoboken: John Wiley & Sons. 2011; pp. 57-92.
[3]
Reardon S. Project ranks billions of drug interactions. Nature 2013; 503(7477): 449-50.
[http://dx.doi.org/10.1038/503449a] [PMID: 24284710]
[4]
Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br J Pharmacol 2011; 162(6): 1239-49.
[http://dx.doi.org/10.1111/j.1476-5381.2010.01127.x PMID: 21091654]
[5]
Krasavin M, Karapetian R, Konstantinov I, et al. Discovery and potency optimization of 2-amino-5-arylmethyl-1,3-thiazole derivatives as potential therapeutic agents for prostate cancer. Arch Pharm (Weinheim) 2009; 342(7): 420-7.
[http://dx.doi.org/10.1002/ardp.200800201] [PMID: 19544302]
[6]
Firuzi LS. Curr Drug Targets 2014; 15: 1177-99.https://doi.org/http://dx.doi.org/10.2174/1389450115666141024113925
[http://dx.doi.org/10.2174/1389450115666141024113925] [PMID: 25341421]
[7]
Veselovsky AV, Zharkova MS, Poroikov VV, Nicklaus MC. Computer-aided design and discovery of protein-protein interaction inhibitors as agents for anti-HIV therapy. SAR QSAR Environ Res 2014; 25(6): 457-71.
[http://dx.doi.org/10.1080/1062936X.2014.898689 PMID: 24716798]
[8]
Song CM, Lim SJ, Tong JC. Recent advances in computer-aided drug design. Brief Bioinform 2009; 10(5): 579-91.https://doi.org/https://doi.org/10.1093/bib/bbp023
[http://dx.doi.org/10.1093/bib/bbp023] [PMID: 19433475]
[9]
Pârvu L. QSAR-a piece of drug design. J Cell Mol Med 2003; 7(3): 333-5.
[http://dx.doi.org/10.1111/j.1582-4934.2003.tb00235.x PMID: 14594559]
[10]
Nolte RT, Wisely GB, Westin S, et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 1998; 395(6698): 137-43.
[http://dx.doi.org/10.1038/25931] [PMID: 9744270]
[11]
Rahman M, Karim M, Ahsan M, Khalipa A, Chowdhury M, Saifuzzaman M. Use of computer in drug design and drug discovery : a review. Int J Pharm Life Sci 2012; 1: 1-21.
[http://dx.doi.org/10.3329/ijpls.v1i2.12955]
[12]
Bharath EN, Manjula S, Vijaychand A. In silico drug design-tool for overcoming the innovation deficit in the drug discovery process. Int J Pharm Pharm Sci 2011; 3: 8-12.
[13]
Sliwoski G, Kothiwale S, Meiler J, Lowe EW Jr. Computational methods in drug discovery. Pharmacol Rev 2013; 66(1): 334-95.
[http://dx.doi.org/10.1124/pr.112.007336] [PMID: 24381236]
[14]
Gilson MK, Zhou H-X. Calculation of protein-ligand binding affinities. Annu Rev Biophys Biomol Struct 2007; 36: 21-42.
[http://dx.doi.org/10.1146/annurev.biophys.36.040306.132550] [PMID: 17201676]
[15]
Yu W, MacKerell AD Jr. Computer-Aided Drug Design Methods. Methods Mol Biol 2017; 1520: 85-106.
[http://dx.doi.org/10.1007/978-1-4939-6634-9_5] [PMID: 27873247]
[16]
Prathipati P, Dixit A, Saxena A. Computer-Aided Drug Design: Integration of Structure-Based and Ligand-Based Approaches in Drug Design. Curr Comp-Aid Drug Des 2007; 3: 133-48.
[http://dx.doi.org/10.2174/157340907780809516]
[17]
Ou-Yang SS, Lu JY, Kong XQ, Liang ZJ, Luo C, Jiang H. Computational drug discovery. Acta Pharmacol Sin 2012; 33(9): 1131-40.
[http://dx.doi.org/10.1038/aps.2012.109] [PMID: 22922346]
[18]
Park H, Hwang KY, Kim YH, Oh KH, Lee JY, Kim K. Discovery and biological evaluation of novel α-glucosidase inhibitors with in vivo anti-diabetic effect. Bioorg Med Chem Lett 2008; 18(13): 3711-5.
[http://dx.doi.org/10.1016/j.bmcl.2008.05.056] [PMID: 18524587]
[19]
Huang HJ, Lee KJ, Yu HW, et al. Structure-based and ligand-based drug design for HER 2 receptor. J Biomol Struct Dyn 2010; 28(1): 23-37.
[http://dx.doi.org/10.1080/07391102.2010.10507341 PMID: 20476793]
[20]
Wold S, Dunn WJ. Multivariate quantitative structure-activity relationships (QSAR): conditions for their applicability. J Chem Inf Comput Sci 1983; 23: 6-13.
[http://dx.doi.org/10.1021/ci00037a002]
[21]
Anderson AC. The process of structure-based drug design. Chem Biol 2003; 10(9): 787-97.
[http://dx.doi.org/10.1016/j.chembiol.2003.09.002] [PMID: 14522049]
[22]
Scapin G. Structural biology and drug discovery. Curr Pharm Des 2006; 12(17): 2087-97.
[http://dx.doi.org/10.2174/138161206777585201] [PMID: 16796557]
[23]
Looger LL, Dwyer MA, Smith JJ, Hellinga HW. Computational design of receptor and sensor proteins with novel functions. Nature 2003; 423(6936): 185-90.
[http://dx.doi.org/10.1038/nature01556] [PMID: 12736688]
[24]
Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov 2004; 3(11): 935-49.
[http://dx.doi.org/10.1038/nrd1549] [PMID: 15520816]
[25]
Leach AR, Dolata DP, Prout K. Automated conformational analysis and structure generation: algorithms for molecular perception. J Chem Inf Comput Sci 1990; 30(3): 316-24.
[http://dx.doi.org/10.1021/ci00067a017] [PMID: 2211887]
[26]
Murrall N, Davies E. Conformational freedom in 3-D databases. 1. Techniques. J Chem Inf Comput Sci 1990; 30: 312-6.
[http://dx.doi.org/10.1021/ci00067a016]
[27]
Hurst T. Flexible 3D searching: the directed tweak technique. J Chem Inf Comput Sci 1994; 34: 190-6.
[http://dx.doi.org/10.1021/ci00017a025]
[28]
Moock T. Conformational Searching in ISIS/3D Databases. J Chem Inf Comput Sci 1994; 34: 184-9.
[http://dx.doi.org/10.1021/ci00017a024]
[29]
Náray-Szabó G, Ferenczy G. Molecular Electrostatics. Chem Rev 1995; 95: 829-47.
[http://dx.doi.org/10.1021/cr00036a002]
[30]
Carrupt P, Testa B, Gaillard P. In Reviews in Computational Chemistry. Wiley-VCH. New York 1997; p. 241.
[31]
Abraham D, Kellogg G. 3D-QSAR in drug design. Leiden: Escom 1993.
[32]
Goodford PJ. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 1985; 28(7): 849-57.
[http://dx.doi.org/10.1021/jm00145a002] [PMID: 3892003]
[33]
Saikia S, Bordoloi M. Molecular Docking: Challenges, Advances and its Use in Drug Discovery Perspective. Curr Drug Targets 2019; 20(5): 501-21. https://doi.org/http://dx.doi.org/10.2174/1389 450119666181022153016
[http://dx.doi.org/10.2174/1389450119666181022153016] [PMID: 30360733]
[34]
Mohan V, Gibbs AC, Cummings MD, Jaeger EP, DesJarlais RL. Docking: successes and challenges. Curr Pharm Des 2005; 11(3): 323-33.
[http://dx.doi.org/10.2174/1381612053382106] [PMID: 15723628]
[35]
Bissantz C, Folkers G, Rognan D. Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. J Med Chem 2000; 43(25): 4759-67.
[http://dx.doi.org/10.1021/jm001044l] [PMID: 11123984]
[36]
Baig MH, Ahmad K, Hasan Q, et al. Interaction of Glucagon G-Protein Coupled Receptor with Known Natural Antidiabetic Compounds: Multiscoring In Silico Approach. Evid Based Complement Alternat Med 2015.2015497253
[http://dx.doi.org/10.1155/2015/497253] [PMID: 26236379]
[37]
Islam B, Sharma C, Adem A, Aburawi E, Ojha S. Insight into the mechanism of polyphenols on the activity of HMGR by molecular docking. Drug Des Devel Ther 2015; 9: 4943-51.
[http://dx.doi.org/10.2147/DDDT.S86705] [PMID: 26357462]
[38]
Peters MB, Raha K, Merz KMJ Jr. Quantum mechanics in structure-based drug design. Curr Opin Drug Discov Devel 2006; 9(3): 370-9.
[PMID: 16729734]
[39]
Sousa SF, Fernandes PA, Ramos MJ. Protein-ligand docking: current status and future challenges. Proteins 2006; 65(1): 15-26.
[http://dx.doi.org/10.1002/prot.21082] [PMID: 16862531]
[40]
Kramer B, Rarey M, Lengauer T. Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking. Proteins 1999; 37(2): 228-41.
[http://dx.doi.org/10.1002/(SICI)1097-0134(19991101)37:2<228:AID-PROT8>3.0.CO;2-8 PMID: 10584068]
[41]
Forli S, Huey R, Pique ME, Sanner MF, Goodsell DS, Olson AJ. Computational protein-ligand docking and virtual drug screening with the AutoDock suite. Nat Protoc 2016; 11(5): 905-19.
[http://dx.doi.org/10.1038/nprot.2016.051] [PMID: 27077332]
[42]
Charifson PS, Corkery JJ, Murcko MA, Walters WP. Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. J Med Chem 1999; 42(25): 5100-9.
[http://dx.doi.org/10.1021/jm990352k] [PMID: 10602695]
[43]
Huang S-Y, Grinter SZ, Zou X. Scoring functions and their evaluation methods for protein-ligand docking: recent advances and future directions. Phys Chem Chem Phys 2010; 12(40): 12899-908.
[http://dx.doi.org/10.1039/c0cp00151a] [PMID: 20730182]
[44]
Hansson T, Oostenbrink C, van Gunsteren W. Molecular dynamics simulations. Curr Opin Struct Biol 2002; 12(2): 190-6.
[http://dx.doi.org/10.1016/S0959-440X(02)00308-1 PMID: 11959496]
[45]
Frenkel D, Smit B. Understanding molecular simulation. In: Academic press, Inc: san diego, CA. 2001.
[46]
Allen M, Tilodesley DJ. Computer simulation of Liquids. Oxford, U.K: Oxford University Press 1989.
[47]
Guido RVC, Oliva G, Andricopulo AD. Virtual screening and its integration with modern drug design technologies. Curr Med Chem 2008; 15(1): 37-46.
[http://dx.doi.org/10.2174/092986708783330683] [PMID: 18220761]
[48]
Hopfinger A, Tokarski J. Three-dimensional quantitative structure-activity relationship analysisPract Appl Comput drug Des. New York: Marcel Dekker 1997; pp. 105-64.
[49]
Hansch C. Quantitative approach to biochemical structure-activity relationships. Acc Chem Res 1969; 2: 232-9.
[http://dx.doi.org/10.1021/ar50020a002]
[50]
Hansch C, Fujita T. p-σ-π Analysis. A Method for the Correlation of Biological Activity and Chemical Structure. J Am Chem Soc 1964; 86: 1616-26.
[http://dx.doi.org/10.1021/ja01062a035]
[51]
Hopfinger AJ, Wang S, Tokarski JS, Jin B, Albuquerque M, Madhav PJ, et al. Construction of 3D-QSAR Models Using the 4D-QSAR Analysis Formalism. J Am Chem Soc 1997; 119: 10509-24.
[http://dx.doi.org/10.1021/ja9718937]
[52]
Patel HM, Noolvi MN, Sharma P, Jaiswal V, Bansal S, Lohan S, et al. Quantitative structure-activity relationship (QSAR) studies as strategic approach in drug discovery. Med Chem Res 2014; 23: 4991-5007.
[http://dx.doi.org/10.1007/s00044-014-1072-3]
[53]
Li WL, Zheng HC, Bukuru J, De Kimpe N. Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. J Ethnopharmacol 2004; 92(1): 1-21.
[http://dx.doi.org/10.1016/j.jep.2003.12.031] [PMID: 15099842]
[54]
Laitonjam W. Traditional medicinal plants of Manipur as anti-diabetics. J Med Plants Res 2011; 5: 677-87.
[55]
Moses CR, Bronson SC. Newer Oral Anti-diabetic drugs 2016; 231-8.
[56]
Kaur P, Mittal A, Nayak SK, Vyas M, Mishra V, Khatik GL. Current Strategies and Drug Targets in the Management of Type 2 Diabetes Mellitus. Curr Drug Targets 2018; 19(15): 1738-66.
[http://dx.doi.org/10.2174/1389450119666180727142902] [PMID: 30051787]
[57]
Deacon CF, Ahrén B, Holst JJ. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? Expert Opin Investig Drugs 2004; 13(9): 1091-102.
[http://dx.doi.org/10.1517/13543784.13.9.1091] [PMID: 15330741]
[58]
Mentlein R. Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides. Regul Pept 1999; 85(1): 9-24.https://doi.org/https://doi.org/10.1016/S0167-0115(99)00089-0
[http://dx.doi.org/10.1016/S0167-0115(99)00089-0 PMID: 10588446]
[59]
Jayasree G, Mukkavalli S, Sahithi A. Docking studies of green tea flavonoids as insulin mimetics. Int J Comput Appl 2011; 30.
[60]
Johnson TO, Ermolieff J, Jirousek MR. Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat Rev Drug Discov 2002; 1(9): 696-709.
[http://dx.doi.org/10.1038/nrd895] [PMID: 12209150]
[61]
Ramachandran C, Kennedy BP. Protein tyrosine phosphatase 1B: a novel target for type 2 diabetes and obesity. Curr Top Med Chem 2003; 3(7): 749-57.
[http://dx.doi.org/10.2174/1568026033452276] [PMID: 12678842]
[62]
Tack CJJ, Smits P. Thiazolidinedione derivatives in type 2 diabetes mellitus. Neth J Med 2006; 64(6): 166-74.
[PMID: 16788214]
[63]
Cantello BCC, Cawthorne MA, Cottam GP, et al. [[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J Med Chem 1994; 37(23): 3977-85.
[http://dx.doi.org/10.1021/jm00049a017] [PMID: 7966158]
[64]
Cohen NC. Guidebook on Molecular Modeling in Drug Design By N C Cohen. Academic Press 1995.
[65]
Perun T, Propst C. Computer aided drug design 1999.
[66]
Bibi S, Kalsoom S, Rashid H. In Silico Approach for Lead Identification and Optimization Of Antidiabetic Compounds. IOSR J Pharm Biol Sci 2013; 3: 36-46.
[67]
Chauhan A, Sharma P, Srivastava P, Kumar N, Dudhe R. Plants Having Potential Anti-diabetic Activity. RE:view 2009; 2.
[68]
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46(1-3): 3-26. https://doi.org/https://doi. org/10.1016/S0169-409X(96)00423-1
[http://dx.doi.org/10.1016/S0169-409X(00)00129-0] [PMID: 11259830]
[69]
Berman HM, Westbrook J, Feng Z, et al. Protein data bank. Nucleic Acids Res 2000; 28(1): 235-42.
[http://dx.doi.org/10.1093/nar/28.1.235] [PMID: 10592235]
[70]
Weigelt J. Structural genomics-impact on biomedicine and drug discovery. Exp Cell Res 2010; 316(8): 1332-8.
[http://dx.doi.org/10.1016/j.yexcr.2010.02.041] [PMID: 20211166]
[71]
Ahmad F, Sudhanshu S, Naz H, Mahto M. Novel drug discovery for diabetes type-2 by pharmacophore, virtual screening and docking of PPARγ. Int J Res Pharm Life Sci 2016; 5: 2134-41.
[72]
Kumaresan R. Structure Based Drug Designing for Diabetes Mellitus. J Proteomics Bioinform 2010; 03
[http://dx.doi.org/10.4172/jpb.1000157]
[73]
Taha MO, Habash M, Hatmal MM, Abdelazeem AH, Qandil A. Ligand-based modeling followed by in vitro bioassay yielded new potent glucokinase activators. J Mol Graph Model 2015; 56: 91-102.https://doi.org/https://doi.org/10.1016/j.jmgm.2014.12.003
[http://dx.doi.org/10.1016/j.jmgm.2014.12.003] [PMID: 25574766]
[74]
Lagos CF, Vecchiola A, Allende F, et al. Identification of novel 11β-HSD1 inhibitors by combined ligand- and structure-based virtual screening. Mol Cell Endocrinol 2014; 384(1-2): 71-82.https://doi.org/https://doi.org/10.1016/j.mce.2014.01.011
[http://dx.doi.org/10.1016/j.mce.2014.01.011] [PMID: 24447464]
[75]
Tanwar O, Tanwar L, Shaquiquzzaman M, Alam MM, Akhter M. Structure based virtual screening of MDPI database: discovery of structurally diverse and novel DPP-IV inhibitors. Bioorg Med Chem Lett 2014; 24(15): 3447-51.
[http://dx.doi.org/10.1016/j.bmcl.2014.05.076] [PMID: 24948564]
[76]
Balaramnavar VM, Srivastava R, Rahuja N, et al. Identification of novel PTP1B inhibitors by pharmacophore based virtual screening, scaffold hopping and docking. Eur J Med Chem 2014; 87: 578-94.https://doi.org/https://doi.org/10.1016/j.ejmech.2014.09.097
[http://dx.doi.org/10.1016/j.ejmech.2014.09.097] [PMID: 25299681]
[77]
Bamane R, Chitre T, Rakholiya V. Molecular docking studies of quinoline-3- carbohydrazide as novel PTP1B inhibitors as potential antihyperglycemic agents. Der Pharma Chem 2011; 3.
[78]
Wu X, Hoffstedt J, Deeb W, et al. Depot-specific variation in protein-tyrosine phosphatase activities in human omental and subcutaneous adipose tissue: a potential contribution to differential insulin sensitivity. J Clin Endocrinol Metab 2001; 86(12): 5973-80.
[http://dx.doi.org/10.1210/jcem.86.12.8109] [PMID: 11739472]
[79]
Srinivasan P, Arumugam DS, Manikandan R, Arulvasu C. Molecular docking studies of 1, 2 disubstituted idopyranose from vitex negundo with anti-diabetic activity of type 2 diabetes. Int J Pharma Bio Sci 2011; 2: 68-83.
[80]
Jiang C, Han S, Chen T, Chen J. 3D-QSAR and docking studies of arylmethylamine-based DPP IV inhibitors. Acta Pharm Sin B 2012; 2: 411-20.
[http://dx.doi.org/10.1016/j.apsb.2012.06.007]
[81]
Ahrén B, Hughes TE. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. Endocrinology 2005; 146(4): 2055-9.
[http://dx.doi.org/10.1210/en.2004-1174] [PMID: 15604213]
[82]
Amuthalakshmi S, Arul Gnana Dhas AS. Insilico design of a ligand for DPP IV in type II diabetes. Adv Biol Res (Faisalabad) 2013; 7: 248-52.
[83]
Kumar S, Khatik GL, Mittal A. Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus. Mini Rev Med Chem 2020; 20(3): 170-82.
[http://dx.doi.org/10.2174/1389557519666191009163519] [PMID: 32134370]
[84]
Kumar S, Khatik GL, Mittal A. In silico Molecular Docking Study to Search New SGLT2 Inhibitor based on Dioxabicyclo[3.2.1] Octane Scaffold. Curr Comput Aided Drug Des 2020; 16(2): 145-54.
[http://dx.doi.org/10.2174/1573409914666181019165821] [PMID: 30345926]
[85]
Sharma MC, Sharma S. Molecular Modeling Studies of Thiophenyl C-Aryl Glucoside SGLT2 Inhibitors as Potential Anti-diabetic Agents. Int J Med Chem 2014.2014739646
[http://dx.doi.org/10.1155/2014/739646] [PMID: 25574393]
[86]
Walia V. Molecular Docking Studies of N-(2-Benzoylphenyl)-L-Tyrosine Derivatives with Anti-Diabetic Activity of Type 2 Diabetes. Pharmatutor 2015.
[87]
Gautier JF, Fetita S, Sobngwi E, Salaün-Martin C. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab 2005; 31(3 Pt 1): 233-42.https://doi.org/https://doi.org/10.1016/S1262-3636(07)70190-8
[http://dx.doi.org/10.1016/S1262-3636(07)70190-8 PMID: 16142014]
[88]
Prajapat R, Bhattacharya I. In-silicoStructure Modeling and Docking Studies Using Dipeptidyl Peptidase 4 (DPP4) Inhibitors against Diabetes Type-2. Adv Diabetes Metab 2016; 4: 73-84.
[http://dx.doi.org/10.13189/adm.2016.040403]
[89]
Bashary R, Khatik GL. Design, and facile synthesis of 1,3 diaryl-3-(arylamino)propan-1-one derivatives as the potential alpha-amylase inhibitors and antioxidants. Bioorg Chem 2019; 82: 156-62.
[http://dx.doi.org/10.1016/j.bioorg.2018.10.010] [PMID: 30321778]
[90]
Kumar P, Sruthi K, Pooja B, Bhanusree G, Fayaz KS. Design, synthesis, insilico molecular docking studies of some new anti-diabetic amino acid esters as potential targets for α- amylase. Mintage J Pharm Med Sci 2017; 6: 7-11.
[91]
Ahmed D, Khan MI, Kaithwas G, Roy S, Gautam S, Singh M, et al. Molecular docking analysis and anti-diabetic activity of Rifabutin against STZ-NA induced diabetes in albino wistar rats. Beni-Suef Univ J Basic Appl Sci 2017; 6: 269-84.
[http://dx.doi.org/10.1016/j.bjbas.2017.04.010]
[92]
Colín-Lozano B, Estrada-Soto S, Chávez-Silva F, et al. Design, synthesis and in combo anti-diabetic bioevaluation of multitarget phenylpropanoic acids. Molecules 2018; 23(2): 1-16.
[http://dx.doi.org/10.3390/molecules23020340] [PMID: 29415496]
[93]
Patel AD, Barot R, Parmar I, et al. Molecular Docking, In-Silico ADMET Study and Development of 1,6- Dihydropyrimidine Derivative as Protein Tyrosine Phosphatase Inhibitor: An Approach to Design and Develop Anti-diabetic Agents. Curr Comput Aided Drug Des 2018; 14(4): 349-62.
[http://dx.doi.org/10.2174/1573409914666180426125721] [PMID: 29701158]
[94]
Abd El-Karim SS, Anwar MM, Syam YM, Nael MA, Ali HF, Motaleb MA. Rational design and synthesis of new tetralin-sulfonamide derivatives as potent anti-diabetics and DPP-4 inhibitors: 2D & 3D QSAR, in vivo radiolabeling and bio distribution studies. Bioorg Chem 2018; 81: 481-93.
[http://dx.doi.org/10.1016/j.bioorg.2018.09.021] [PMID: 30243239]
[95]
Asadollahi-Baboli M, Dehnavi S. Docking and QSAR analysis of tetracyclic oxindole derivatives as α-glucosidase inhibitors. Comput Biol Chem 2018; 76: 283-92.
[http://dx.doi.org/10.1016/j.compbiolchem.2018.07.019 PMID: 30103106]
[96]
Sun H, Zhang Y, Ding W, et al. Inhibitory activity evaluation and mechanistic studies of tetracyclic oxindole derivatives as α-glucosidase inhibitors. Eur J Med Chem 2016; 123: 365-78.
[http://dx.doi.org/10.1016/j.ejmech.2016.07.044] [PMID: 27487567]
[97]
Herrera-Rueda MÁ, Tlahuext H, Paoli P, et al. Design, synthesis, in vitro, in vivo and in silico pharmacological characterization of anti-diabetic N-Boc-l-tyrosine-based compounds. Biomed Pharmacother 2018; 108: 670-8.
[http://dx.doi.org/10.1016/j.biopha.2018.09.074] [PMID: 30245467]
[98]
Watterson KR, Hudson BD, Ulven T, Milligan G. Treatment of type 2 diabetes by free Fatty Acid receptor agonists. Front Endocrinol (Lausanne) 2014; 5: 137.
[http://dx.doi.org/10.3389/fendo.2014.00137] [PMID: 25221541]
[99]
Li Z, Xu X, Liu R, Deng F, Zeng X, Zhang L. Nitric oxide donor-based FFA1 agonists: Design, synthesis and biological evaluation as potential anti-diabetic and anti-thrombotic agents. Bioorg Med Chem 2018; 26(15): 4560-6.
[http://dx.doi.org/10.1016/j.bmc.2018.07.050] [PMID: 30082106]
[100]
Luthra T, Naga Lalitha K, Agarwal R, Uma A, Sen S. Design, synthesis and in vitro study of densely functionalized oxindoles as potent α-glucosidase inhibitors. Bioorg Med Chem 2018; 26(18): 4996-5005.
[http://dx.doi.org/10.1016/j.bmc.2018.08.022] [PMID: 30153956]
[101]
Mohammadi-Khanaposhtani M, Rezaei S, Khalifeh R, et al. Design, synthesis, docking study, α-glucosidase inhibition, and cytotoxic activities of acridine linked to thioacetamides as novel agents in treatment of type 2 diabetes. Bioorg Chem 2018; 80: 288-95.https://doi.org/https://doi.org/10.1016/j.bioorg.2018.06.035
[http://dx.doi.org/10.1016/j.bioorg.2018.06.035] [PMID: 29980114]
[102]
Nasli-Esfahani E, Mohammadi-Khanaposhtani M, Rezaei S, et al. A new series of Schiff base derivatives bearing 1,2,3-triazole: Design, synthesis, molecular docking, and α-glucosidase inhibition. Arch Pharm (Weinheim) 2019; 352(8)e1900034
[http://dx.doi.org/10.1002/ardp.201900034] [PMID: 31330079]
[103]
Feng X-Y, Jia W-Q, Liu X, et al. Identification of novel PPARα/γ dual agonists by pharmacophore screening, docking analysis, ADMET prediction and molecular dynamics simulations. Comput Biol Chem 2019; 78: 178-89.
[http://dx.doi.org/10.1016/j.compbiolchem.2018.11.023 PMID: 30557816]
[104]
Ibrahim MT, Uzairu A, Shallangwa GA, Ibrahim A. In-silico studies of some oxadiazoles derivatives as anti-diabetic compounds. J King Saud Univ-Sci 2020; 32: 423-32.https://doi.org/https://doi.org/10.1016/j.jksus.2018.06.006
[105]
Kaur P, Bhat ZR, Bhat S, et al. Synthesis and evaluation of new 1,2,4-oxadiazole based trans- acrylic acid derivatives as potential PPAR-alpha/gamma dual agonist. Bioorg Chem 2020.100103867
[http://dx.doi.org/10.1016/j.bioorg.2020.103867] [PMID: 32353564]
[106]
Gejalakshmi S, Harikrishnan N, Thillia Govindrajan E, Divyasri A. Microwave assisted synthesis of tetrahydropyrmidine and in silico screening of anti-diabetic drug. Int J Curr Pharm Res 2020; 12.
[http://dx.doi.org/10.22159/ijcpr.2020v12i1.36821]
[107]
Banerjee M, Sahoo S, Sahu S. In silico designing and molecular docking studies on selected reported & proposed new compounds against ppar-γ receptor for type-2-diabetes. World J Pharm Pharm Sci 2016; 5: 1022-30.
[108]
Kulkarni S, Gupta P, Pallavi A. Investigation of Enzymes Binding to “Voglibose- an Anti-diabetic Drug” and the Choice of Enzyme to be Used for Biosensing. Br J Pharm Res 2017; 14: 1-10.
[http://dx.doi.org/10.9734/BJPR/2016/30369]
[109]
Angadi KK, Gundampati R, Jagannadham MV, Kandru A. Molecular docking studies of guggultetrol from nymphaea pubescens with target glucokinase (GK) related to type-ii diabetes. J Appl Pharm Sci 2013; 3: 127-31.
[http://dx.doi.org/10.7324/JAPS.2013.30222]
[110]
Middha SK, Goyal AK, Faizan SA, Sanghamitra N, Basistha BC, Usha T. In silico-based combinatorial pharmacophore modelling and docking studies of GSK-3β and GK inhibitors of Hippophae. J Biosci 2013; 38(4): 805-14.
[http://dx.doi.org/10.1007/s12038-013-9367-y] [PMID: 24287660]
[111]
Goyal AK, Basistha BC, Sen A, Middha SK. Antioxidant profiling of Hippophae salicifolia growing in sacred forests of Sikkim, India. Funct Plant Biol 2011; 38(9): 697-701.
[http://dx.doi.org/10.1071/FP11016] [PMID: 32480925]
[112]
Bharti SK, Kumar A, Sharma NK, et al. Tocopherol from seeds of Cucurbita pepo against diabetes: validation by in vivo experiments supported by computational docking. J Formos Med Assoc 2013; 112(11): 676-90.
[http://dx.doi.org/10.1016/j.jfma.2013.08.003] [PMID: 24344360]
[113]
Jayasree G, Swarna S. Molecular docking studies of anti-diabetic activity of cinnamon compounds. Asian J Pharm Clin Res 2014; 7: 31-4.
[114]
Kim SH, Hyun SH, Choung SY. Anti-diabetic effect of cinnamon extract on blood glucose in db/db mice. J Ethnopharmacol 2006; 104(1-2): 119-23.
[http://dx.doi.org/10.1016/j.jep.2005.08.059] [PMID: 16213119]
[115]
Esther GS, Manonmani AJ. Molecular docking studies of Ellagic acid and Gallic acid in diabetic nephropathy. Int J Drug Dev Res 2014; 6: 248-58.
[116]
Singh DR. Morinda citrifolia L (Noni): A review of the scientific validation for its nutritional and therapeutic properties. J Diabetes Endocrinol 2012; 3: 77-91.
[http://dx.doi.org/10.5897/JDE10.006]
[117]
Awaluddin F, Mas Jaya Putra A, Supandi S. Molecular Docking Studies of Flavonoids of Noni Fruit (Morinda citrifolia L) to Peroxisome Proliferator-Activated Receptor-Gamma. PPAR 2015.
[http://dx.doi.org/10.2991/iccst-15.2015.18]
[118]
Jain A, Gupta P. In silico Comparative Molecular Docking Study and Analysis of Glycyrrhizin from Abrus precatorius (L.) against Antidiabetic Activity. European J Med Plants 2015; 6: 212-22.
[http://dx.doi.org/10.9734/EJMP/2015/13855]
[119]
Müller BM, Franz G. Chemical structure and biological activity of polysaccharides from Hibiscus sabdariffa. Planta Med 1992; 58(1): 60-7.
[http://dx.doi.org/10.1055/s-2006-961391] [PMID: 1620746]
[120]
Nerdy N. In silico docking of chemical compounds from Roselle Calyces (Hibiscus sabdariffa L.) as anti-diabetic. Int J Chemtech Res 2015; 7: 148-52.
[121]
Shahinozzaman M, Taira N, Ishii T, Halim MA, Hossain MA, Tawata S. Anti-Inflammatory, Anti-Diabetic, and Anti-Alzheimer’s Effects of Prenylated Flavonoids from Okinawa Propolis: An Investigation by Experimental and Computational Studies. Molecules 2018; 23(10)E2479
[http://dx.doi.org/10.3390/molecules23102479] [PMID: 30262742]
[122]
Hossain MU, Khan MA, Rakib-Uz-Zaman SM, et al. Treating Diabetes Mellitus: Pharmacophore Based Designing of Potential Drugs from Gymnema sylvestre against Insulin Receptor Protein. BioMed Res Int 2016.20163187647
[http://dx.doi.org/10.1155/2016/3187647] [PMID: 27034931]
[123]
Bansode T, Salalkar B. Strategies In The Design Of Anti-diabetic Drugs From Terminalia Chebula Using In Silico And In Vitro Approach. MicroMedicine 2016; 4: 60-7.
[http://dx.doi.org/10.5281/zenodo.167869]
[124]
Davies JW, Glick M, Jenkins JL. Streamlining lead discovery by aligning in silico and high-throughput screening. Curr Opin Chem Biol 2006; 10(4): 343-51.
[http://dx.doi.org/10.1016/j.cbpa.2006.06.022] [PMID: 16822701]
[125]
Bharatam PV, Patel DS, Adane L, Mittal A, Sundriyal S. Modeling and informatics in designing anti-diabetic agents. Curr Pharm Des 2007; 13(34): 3518-30.
[http://dx.doi.org/10.2174/138161207782794239] [PMID: 18220788]
[126]
Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 2010; 9(3): 203-14.
[http://dx.doi.org/10.1038/nrd3078] [PMID: 20168317]

Rights & Permissions Print Cite
Article Metrics
48
1
© 2024 Bentham Science Publishers | Privacy Policy